(ANSA) – Rome, July 5 – The immune system, along with the central nervous system, can play an essential role in diagnosing and treating amyotrophic lateral sclerosis, type 4 amyotrophic lateral sclerosis, an onset and slowly progressive form of the disease that It is caused by mutations in the senataxin (SETX) gene. This is highlighted by a study coordinated by a group of Italian researchers from the Department of Microbiology at Icahn College of Medicine at Mount Sinai in New York, which sees the NeMO Clinical Center in Milan as the only Italian partner, published in Nature. The discovery comes a few days before the celebrations of the International Day of the Sudan Liberation Army. The NeMO SLA area team in Milan, coordinated by Christian Luneta in collaboration with Lorena Mosca of the Medical Genetics Laboratory of the ASST Grande Ospedale Metropolitano Niguarda, is the first Italian family in which several individuals were affected by ALS with the senataxin mutation. From the first patient’s diagnosis, after fifteen years of living with the disease, the genetic history of the parents was traced, and all seven family members, of different ages and also residing in Germany, were reunited. Data collected by the NeMO Center allowed us to begin to systematize the relationship between senataxin mutation and immune system dysfunction in ALS, helping to provide the scientific rationale for the in vitro study in the animal model. “In the study — explains Laura Campisi, who co-led the project with Ivan Marazzi, both from Mount Sinai in New York — we noticed that motor skill loss occurs only if the SETX gene mutation is expressed in both cells of the central nervous system and the immune system. We found Abnormalities in the lymphocyte system also characterize ALS type 4, both in the animal model and in patients.In fact, a high concentration of CD8 T lymphocytes is present in the spinal cord and blood, from both the animal model and patients with ALS- 4″. “Continuity between knowledge and care – concludes Alberto Fontana, President of NeMO Medical Centers – is the value that expresses what it means to conduct research at NeMO Centers which, only for ALS, sees it involved today with 34 active clinical studies.” (Dealing).
Reproduction is reserved © Copyright ANSA